Maloth S, Shrinivas TR, Krishna Pramod B, Nagarathna P. Prevalence of oromucosal lesions in HIV positive patients receiving haart-A prospective clinical study.
J Family Med Prim Care 2020;
9:4821-4825. [PMID:
33209807 PMCID:
PMC7652119 DOI:
10.4103/jfmpc.jfmpc_881_20]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2020] [Revised: 06/14/2020] [Accepted: 07/20/2020] [Indexed: 01/29/2023] Open
Abstract
AIM
To determine the preponderance of oral mucosal lesions and conditions in patients receiving highly active antiretroviral therapy (HAART) for Human Immunodeficiency virus (HIV).
MATERIAL AND METHODS
Patient tested Seropositive for HIV and on HAART therapy were clinically examined to evaluate prevalence of oral lesions.
RESULTS
In the pool of 152 HIV positive patients in the study, age ranged from 7 to 71 years, 67 were males and 85 females. The duration of the HAART medication was 43 months. Oral lesion was present in 51.32% of patients related to infection. Oral lesions seen in descending order of frequency were periodontitis, mucosal hyperpigmentation, acute gingivitis, oral candidiasis, linear gingival erythema, stomatitis, and nonspecific ulcers. Totally, 48.68% of patients had no oral lesions.
CONCLUSION
Majority of the HIV patients on HAART exhibited periodontitis (30.77%), mucosal hyperpigmentation (17.44%), gingivitis (10.77%), anemic stomatitis (11.28%), and other oral lesions accounted to 29.74% which may be attributed to Anti Retro Viral Therapy.
Collapse